Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Quinto J Gesiotto, MD, David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Chetasi Talati, MD, Kendra L. Sweet, MD MS, Jeffrey E. Lancet, MD, Rami Komrokji, MD, David A. Sallman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140861

Published: 2020

Journal Articles

Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis

Franco Castillo Tokumori, MD, Chetasi Talati, MD, Najla E. Al Ali, David A. Sallman, MD, Seongseok Yun, MDPhD, Kendra L. Sweet, MD MS, Eric Padron, MD, Jeffrey E. Lancet, MD, Rami Komrokji, MD, Andrew T. Kuykendall, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-140145

Published: 2020

Journal Articles

Large Granular Lymphocytic Leukemia with Coexisting Malignancies

Ning Dong, MD, Leidy Isenalumhe, MD, Yumeng Zhang, MD, Franco Castillo Tokumori, MD, Todd C. Knepper, PharmD, Rami Komrokji, MD, Ling Zhang, MD, Haipeng Shao, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136796

Published: 2020

Journal Articles

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

John Mascarenhas, MD, Heidi E. Kosiorek, MS, Lilian Varricchio, PhD, Rupali Bhave, MD, Andrew T. Kuykendall, MD, Rami Komrokji, MD, Aaron T. Gerds, MDMS, Jeanne M. Palmer, MD, Amelia R. Gabler, Lonette Sandy, Anna Rita Migliaccio, PhD, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Maureen O'Connor-McCourt, PhD, Gilles Tremblay, PhD, Paul I. Nadler, MD, Amylou C. Dueck, PhD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-140830

Published: 2020

Journal Articles

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Mohammad O Hussaini, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD MS, David A. Sallman, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140885

Published: 2020

Journal Articles

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140317

Published: 2020

Journal Articles

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD PhD MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, MD MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-139815

Published: 2020

Journal Articles

Clinical Characteristics and Outcomes of Patients with Large Granular Lymphocytic Leukemia Treated with Methotrexate, Cyclophosphamide or Cyclosporine. a Large Single Institutional Retrospective Analysis

Ankita Tandon, DO, Ning Dong, MD, Yumeng Zhang, MD, Emilie Wang, MD, Todd C. Knepper, PharmD, Haipeng Shao, MD, Ling Zhang, MD, Leidy Isenalumhe, MD, Rami Komrokji, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-141701

Published: 2020

Journal Articles

SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Onyee Chan, MD, Najla Al Ali, MD, David A. Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141960

Published: 2020

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

Journal Articles

Novel Therapeutic Approach to Improve Hematopoiesis By Targeting Myeloid Derived Suppressor Cells with a Humanized Anti-CD33 Antibody

Erika A Eksioglu, PhD, Karl-Heinz Heider, PhD, Bjoern Rueter, MD, Alexis Burnette, Max Wei, Kathy McGraw, Ashley A Basiorka, Parthik Patel, Jeffrey Lancet, Rami Komrokji, MD, Alan F. List, MD, Sheng Wei, MD

Blood (2014) 124 (21): 4597.

https://doi.org/10.1182/blood.V124.21.4597.4597

Published: 2014

Journal Articles

Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide

Dana E Rollison, PhD, Kenneth H. Shain, MD PhD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, Kate Fisher, MA, Najla H Al Ali, Eric Padron, MD, Jeff E Lancet, MD, Marta Olesnyckyj, Laurie Kenvin, BSN, RN, Robert D. Knight, MD, William Dalton, PhD MD, Alan F. List, MD, Rami Komrokji, MD

Blood (2014) 124 (21): 413.

https://doi.org/10.1182/blood.V124.21.413.413

Published: 2014

Journal Articles

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Dana E Rollison, PhD, Rami Komrokji, MD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, William Fulp, Kate Fisher, MA, Rachid Baz, MD, Taiga Nishihori, MD, Marta Olesnyckyj, Laurie Kenvin, BSN, RN, Robert D. Knight, MD, Daniel M Sullivan, MD, Melissa Alsina, MD, William Dalton, PhD MD, Kenneth H. Shain, MD PhD

Blood (2014) 124 (21): 2129.

https://doi.org/10.1182/blood.V124.21.2129.2129

Published: 2014

Journal Articles

Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients

Dana E Rollison, PhD, Kenneth H. Shain, MD PhD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, William Fulp, Kate Fisher, MA, Najla H Al Ali, Eric Padron, MD, Jeffrey Lancet, Qiang Xu, PhD, Robert D. Knight, MD, Alan F. List, MD, William Dalton, PhD MD, Rami Komrokji, MD

Blood (2014) 124 (21): 1912.

https://doi.org/10.1182/blood.V124.21.1912.1912

Published: 2014

Journal Articles

Overall Survival in Acute Erythroleukemia According to Pathologic Features.

Xiaohui Zhang, Alan F List, MD, Rami Komrokji, MD, Jeffrey E Lancet, MD, Lynn Moscinski, MD, Ling Zhang, MD

Blood (2012) 120 (21): 2597.

https://doi.org/10.1182/blood.V120.21.2597.2597

Published: 2012

Journal Articles

Importance of T-Cell Proliferative Stress In Myelodysplastic Syndrome

Lili Yang, PhD, Amber Schmidt, Undergraduate, Rami Komrokji, MD, Jeffrey S. Painter, BS, Ashley Cole, Alan F. List, MD, Dana E. Rollison, PhD, P.K. Epling-Burnette, PharmD, PhD

Blood (2010) 116 (21): 2939.

https://doi.org/10.1182/blood.V116.21.2939.2939

Published: 2010

Journal Articles

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Francine Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Eric Jacobsen, MD, Ranjana Advani, MD, Mitchell Smith, MD, PhD, Rami Komrokji, MD, Kelly Pendergrass, MD, Vanessa Bolejack, MPH, Karen Watts, Mark Acosta, PharmD

Blood (2007) 110 (11): 3449.

https://doi.org/10.1182/blood.V110.11.3449.3449

Published: 2007

Journal Articles

A Predictive Model for Chemotherapy-Associated Thrombosis Based on Findings from a Prospective Outpatient Registry.

Alok A. Khorana, MD, Charles W. Francis, MD, Eva Culakova, PhD, Rami Komrokji, MD, Nikhil Uppal, MD, Gary H. Lyman, MD

Blood (2004) 104 (11): 2586.

https://doi.org/10.1182/blood.V104.11.2586.2586

Published: 2004

NARROW

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis

Large Granular Lymphocytic Leukemia with Coexisting Malignancies

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Clinical Characteristics and Outcomes of Patients with Large Granular Lymphocytic Leukemia Treated with Methotrexate, Cyclophosphamide or Cyclosporine. a Large Single Institutional Retrospective Analysis

SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Novel Therapeutic Approach to Improve Hematopoiesis By Targeting Myeloid Derived Suppressor Cells with a Humanized Anti-CD33 Antibody

Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients

Overall Survival in Acute Erythroleukemia According to Pathologic Features.

Importance of T-Cell Proliferative Stress In Myelodysplastic Syndrome

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

A Predictive Model for Chemotherapy-Associated Thrombosis Based on Findings from a Prospective Outpatient Registry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only